XTRA:BAYNPharmaceuticals
Why Bayer (XTRA:BAYN) Is Up 6.5% After Gene Therapy, AI Drug Discovery Updates – And What's Next
In early January 2026, Bayer’s gene therapy subsidiary AskBio reported that the FDA had accepted its IND for AB-1009, a Fast Track- and Orphan Drug-designated AAV gene therapy for late-onset Pompe disease, while Bayer also disclosed new alliances in heart-targeted siRNA and AI-driven antibody design.
Together, these pipeline and collaboration updates highlight Bayer’s increasing emphasis on advanced genetic medicines and AI-enabled R&D to reinforce its pharmaceuticals portfolio.
We’ll now...